Yoon B H, Romero R, Kim M, Kim E C, Kim T, Park J S, Jun J K
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, and the Laboratory of Fetal Medicine Research, Clinical Research Institute, Seoul National University Hospital, Korea.
Am J Obstet Gynecol. 2000 Nov;183(5):1130-7. doi: 10.1067/mob.2000.109036.
The objective of this study was to determine the frequency and clinical significance of the detection of Ureaplasma urealyticum by means of the polymerase chain reaction with specific primers in the amniotic fluid of patients with preterm premature rupture of membranes.
Amniocentesis was performed in 154 patients with preterm premature rupture of membranes. Amniotic fluid was cultured for aerobic and anaerobic bacteria and for mycoplasmas. Ureaplasma urealyticum was detected by means of the polymerase chain reaction with specific primers. Patients were divided into the following 3 groups according to the results of amniotic fluid culture and polymerase chain reaction for U. urealyticum: those with a negative amniotic fluid culture and a negative polymerase chain reaction (n = 99), those with a negative amniotic fluid culture but a positive polymerase chain reaction (n = 18), and those with a positive amniotic fluid culture regardless of the results of the polymerase chain reaction (n = 37). Contingency table and survival techniques were used for analysis.
(1) U. urealyticum was detected by polymerase chain reaction in 28% (43/154) of patients and by culture in 16% (25/154). (2) Among the 43 patients with a positive polymerase chain reaction for U urealyticum, amniotic fluid culture was negative in 42% (18/43). (3) Patients with a negative amniotic fluid culture for U urealyticum but a positive polymerase chain reaction had a significantly shorter median interval from amniocentesis to delivery and a higher amniotic fluid interleukin 6 and white blood cell count than did those with a negative amniotic fluid culture and a negative polymerase chain reaction (interval to delivery; median, 53 hours; range, 0.3-335 hours; vs. median, 141 hours; range, 0.1-3552 hours; P<.05; amniotic fluid white blood cell count: median, 513 cells/mm(3); range, 1-2295 cells/mm(3); vs. median, 1 cell/mm(3); range, 0-7956 cells/mm(3); amniotic fluid interleukin 6: median, 16.6 ng/mL; range, 0.3-53.0 ng/mL; vs. median 0.4 ng/mL; range, 0-69.8 ng/mL; P<.0001 for all). (4) Patients with a positive polymerase chain reaction for U. urealyticum but a negative amniotic fluid culture had a higher rate of significant neonatal morbidity than did those with both a negative culture and a negative polymerase chain reaction (P<.05). (5) No significant differences in perinatal outcome were observed between patients with a negative culture but a positive polymerase chain reaction and those with a positive amniotic fluid culture.
(1) Culture techniques for mycoplasmas missed 40% of cases of microbial invasion of the amniotic cavity with U. urealyticum. (2) Patients with a positive polymerase chain reaction but a negative amniotic fluid culture are at risk for adverse outcomes. (3) The use of molecular microbiologic techniques is likely to increase the detection of infection among patients with obstetric complications.
本研究的目的是通过使用特异性引物的聚合酶链反应来确定胎膜早破患者羊水中解脲脲原体检测的频率及其临床意义。
对154例胎膜早破患者进行了羊膜腔穿刺术。对羊水进行需氧菌、厌氧菌和支原体培养。通过使用特异性引物的聚合酶链反应检测解脲脲原体。根据羊水培养结果和解脲脲原体的聚合酶链反应结果将患者分为以下3组:羊水培养阴性且聚合酶链反应阴性的患者(n = 99),羊水培养阴性但聚合酶链反应阳性的患者(n = 18),以及无论聚合酶链反应结果如何羊水培养阳性的患者(n = 37)。使用列联表和生存技术进行分析。
(1)通过聚合酶链反应在28%(43/154)的患者中检测到解脲脲原体,通过培养在16%(25/154)的患者中检测到。(2)在43例解脲脲原体聚合酶链反应阳性的患者中,42%(18/43)的羊水培养为阴性。(3)羊水培养解脲脲原体阴性但聚合酶链反应阳性的患者从羊膜腔穿刺到分娩的中位间隔时间明显短于羊水培养阴性且聚合酶链反应阴性的患者,羊水白细胞介素6和白细胞计数也更高(分娩间隔时间;中位值,53小时;范围,0.3 - 335小时;相比之下,中位值,141小时;范围,0.1 - 3552小时;P<.05;羊水白细胞计数:中位值,513个细胞/mm³;范围,1 - 2295个细胞/mm³;相比之下,中位值,1个细胞/mm³;范围,0 - 7956个细胞/mm³;羊水白细胞介素6:中位值,16.6 ng/mL;范围,0.3 - 53.0 ng/mL;相比之下,中位值0.4 ng/mL;范围,0 - 69.8 ng/mL;所有P<.0001)。(4)解脲脲原体聚合酶链反应阳性但羊水培养阴性的患者发生严重新生儿疾病的发生率高于培养和聚合酶链反应均为阴性的患者(P<.05)。(5)培养阴性但聚合酶链反应阳性的患者与羊水培养阳性的患者之间围产期结局无显著差异。
(1)支原体培养技术漏诊了40%的解脲脲原体引起的羊膜腔微生物感染病例。(2)聚合酶链反应阳性但羊水培养阴性的患者有不良结局的风险。(3)使用分子微生物学技术可能会增加产科并发症患者感染的检测率。